Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -18.20% is 74% above its 4-year average of -70.72%, near the high end of its 4-year range (-422.78%–-7.49%).
As of the fiscal period ended Tuesday, June 30, 2026. 88.27% above its 12-month average of -155.09%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -18.20%.
RETURN ON INVESTED CAPITAL (ROIC)
-18.20%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-155.09%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-104.25%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+88.27%
CURRENT VS 3Y AVG
+82.55%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
+48.95%
vs the sector median at left
Immix Biopharma, Inc.
Market Cap
$524.43M
Return on Invested Capital (ROIC)
-18.20%
TTM Avg
-155.09%
3Y Avg
-104.25%
5Y Avg
N/A
Market Cap
$529.58M
Return on Invested Capital (ROIC)
-26.20%
TTM Avg
-79.72%
3Y Avg
-69.70%
5Y Avg
-51.08%
Market Cap
$519.25M
Return on Invested Capital (ROIC)
-19.47%
TTM Avg
-57.88%
3Y Avg
-52.57%
5Y Avg
-47.02%
Market Cap
$531.52M
Return on Invested Capital (ROIC)
-317.86%
TTM Avg
-177.04%
3Y Avg
-169.25%
5Y Avg
-196.25%
Market Cap
$531.98M
Return on Invested Capital (ROIC)
-0.81%
TTM Avg
-8.59%
3Y Avg
-110.96%
5Y Avg
-102.03%
Market Cap
$516.76M
Return on Invested Capital (ROIC)
-56.99%
TTM Avg
-66.45%
3Y Avg
-57.50%
5Y Avg
-60.06%
Market Cap
$533.04M
Return on Invested Capital (ROIC)
-16.89%
TTM Avg
-20.74%
3Y Avg
-75.97%
5Y Avg
-65.59%
Market Cap
$538.01M
Return on Invested Capital (ROIC)
-78.31%
TTM Avg
-49.75%
3Y Avg
-41.99%
5Y Avg
-101.04%
Market Cap
$505.87M
Return on Invested Capital (ROIC)
-18.90%
TTM Avg
-35.16%
3Y Avg
-27.40%
5Y Avg
-20.34%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | $524.43M | -18.20% | -155.09% | -104.25% | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $529.58M | -26.20% | -79.72% | -69.70% | -51.08% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -19.47% | -57.88% | -52.57% | -47.02% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | -317.86% | -177.04% | -169.25% | -196.25% |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | -0.81% | -8.59% | -110.96% | -102.03% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | -56.99% | -66.45% | -57.50% | -60.06% |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | -16.89% | -20.74% | -75.97% | -65.59% |
| ProKidney Corp. (PROK)vs › | $538.01M | -78.31% | -49.75% | -41.99% | -101.04% |
| 908 Devices Inc. (MASS)vs › | $505.87M | -18.90% | -35.16% | -27.40% | -20.34% |
| Crescent Biopharma, Inc. (CBIO)vs › | $504.04M | -102.59% | -133.31% | -119.78% | -99.25% |
ROIC
-18.2%
ROE
-17.4%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -18.20% |
| 2026-03-31 | -42.31% |
| 2025-12-31 | -31.62% |
| 2025-09-30 | -260.57% |
| 2025-06-30 | -422.78% |
| 2025-03-31 | -205.65% |
| 2024-12-31 | -159.00% |
| 2024-09-30 | -124.15% |
| 2024-06-30 | -80.98% |
| 2024-03-31 | -66.96% |
| 2023-12-31 | -99.62% |
| 2023-09-30 | -74.10% |
| 2023-06-30 | -87.84% |
| 2023-03-31 | -80.16% |
| 2022-12-31 | -60.28% |
| 2022-09-30 | -29.99% |
| 2022-06-30 | -21.19% |
| 2022-03-31 | -12.79% |
| 2021-12-31 | -7.49% |
